These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 1227069)
21. [Should the use of oral contraceptives be stopped by the age of 40?]. Halttunen M Duodecim; 2002; 118(16):1629-30. PubMed ID: 12271939 [No Abstract] [Full Text] [Related]
22. [Significance of hereditary thrombophilia for risk of thrombosis with oral contraceptives]. Bauersachs R; Lindhoff-Last E; Ehrly AM; Kuhl H Zentralbl Gynakol; 1996; 118(5):262-70. PubMed ID: 8701622 [TBL] [Abstract][Full Text] [Related]
23. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception; 1998 May; 57(5):315-24. PubMed ID: 9673838 [TBL] [Abstract][Full Text] [Related]
24. Oral contraception for women in their 40s. Mishell DR; Connell E; Haney A; Hodgen G; Speroff L J Reprod Med; 1990 Apr; 35(4 Suppl):447-81. PubMed ID: 2186168 [No Abstract] [Full Text] [Related]
25. [Metabolic and vascular consequences of hormonal contraception in non-diabetics]. Basdevant A; Guy-Grand B Journ Annu Diabetol Hotel Dieu; 1983; ():223-37. PubMed ID: 6358613 [No Abstract] [Full Text] [Related]
26. A serial method of ovulation control using ethinyl oestradiol to suppress ovulation. McBride WG Med J Aust; 1966 Jan; 1(5):172-4. PubMed ID: 5908316 [No Abstract] [Full Text] [Related]
27. [Oral contraceptives: update]. Fugère P Union Med Can; 1983 Feb; 112(2):109-12. PubMed ID: 6845551 [No Abstract] [Full Text] [Related]
28. [Risks of contraception: vascular diseases]. Genz HJ; Ludwig H Ther Umsch; 1986 May; 43(5):388-91. PubMed ID: 3726774 [No Abstract] [Full Text] [Related]
29. [Side effects and especially uterine bleeding in women taking oral contraceptives]. Bygdeman M; Svensson G; Westerholm B Lakartidningen; 1972 Dec; 69():Suppl 4:42-6. PubMed ID: 4656848 [No Abstract] [Full Text] [Related]
30. Assessing the risk of ovulation in interaction studies of drugs and oral contraceptives. de la Rey N; Schall R; Luus HG; Meyer BH; Müller FO Int J Clin Pharmacol Ther Toxicol; 1993 Sep; 31(9):435-9. PubMed ID: 8225692 [TBL] [Abstract][Full Text] [Related]
31. [Neurologic complications after oral contraceptives]. Orzechowska M; Poźniak-Patewicz E; Rosset SO Wiad Lek; 1970 Dec; 23(24):2199-201. PubMed ID: 5532005 [No Abstract] [Full Text] [Related]
32. [Cardiovascular side effects resulting from oral contraceptives]. Engel HJ; Lichtlen P Ther Umsch; 1980 Feb; 37(2):96-104. PubMed ID: 7385086 [TBL] [Abstract][Full Text] [Related]
33. [Branch retinal artery occlusion after longterm prophylaxis with ovulation inhibitors (author's transl)]. Fulmek R Klin Monbl Augenheilkd; 1974 Mar; 164(3):371-7. PubMed ID: 4848161 [No Abstract] [Full Text] [Related]
36. Benefits and risk of oral contraceptives. A reassessment. Burkman RT J Reprod Med; 1991 Mar; 36(3 Suppl):217-8. PubMed ID: 2046074 [No Abstract] [Full Text] [Related]
37. [New generation of oral contraceptives and the cardiovascular effects]. Ben-Arie A; Hagay Z Harefuah; 1997 Aug; 133(3-4):111-5. PubMed ID: 9332078 [No Abstract] [Full Text] [Related]
38. The pill, breast and cervical cancer, and the role of progestogens in arterial disease. Lincoln R Fam Plann Perspect; 1984; 16(2):55-63. PubMed ID: 6373360 [No Abstract] [Full Text] [Related]